Streptococcus pneumoniae is the main causative agent of community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 608s Year: 2002
Streptococcus pneumoniae resistance pattern and its clinical implicationsSource: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006
MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009
Pulmonary disease as a risk factor for community-acquired pneumonia caused by multiple pathogens, including Streptococcus pneumoniae Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001
Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008
Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009
Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010
Is Chlamydia pneumoniae an important pathogen in patients with community-acquired pneumonia? Source: Eur Respir J 2003; 21: 741-742 Year: 2003
MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009
Streptococcus pneumoniae infection is an independent cause of cardiac rhythm alteration in community-acquired pneumonia Source: International Congress 2015 – Prognostic factors in pneumonia: from clinical observations to experimental models Year: 2015
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009
Levofloxacin non-susceptible streptococcus pneumoniae in community-acquired respiratory infection; prevalence and risk factors Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008
Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
The impact of antibiotic resistance in the management of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=131 Year: 2004
Future antibiotics and current practices for treating respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=255 Year: 2004
S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistanceSource: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016